UNLABELLED: The diagnosis and management of drug-induced liver injury (DILI) is hindered by the limited utility of traditional clinical chemistries. It has recently been shown that hepatotoxicants can produce compound-specific changes in the peripheral blood (PB) transcriptome in rodents, suggesting that the blood transcriptome might provide new biomarkers of DILI. To investigate in humans, we used DNA microarrays as well as serum metabolomic methods to characterize changes in the transcriptome and metabolome in serial PB samples obtained from six healthy adults treated with a 4-g bolus dose of acetaminophen (APAP) and from three receiving placebo. Treatment did not cause liver injury as assessed by traditional liver chemistries. However, 48 hours after exposure, treated subjects showed marked down-regulation of genes involved in oxidative phosphorylation/mitochondrial function that was not observed in the placebos (P < 1.66E-19). The magnitude of down-regulation was positively correlated with the percent of APAP converted to the reactive metabolite N-acetyl-p-benzoquinone-imide (NAPQI) (r= 0.739;P= 0.058). In addition, unbiased analysis of the serum metabolome revealed an increase in serum lactate from 24 to 72 hours postdosing in the treated subjects alone (P< 0.005). Similar PB transcriptome changes were observed in human overdose patients and rats receiving toxic doses. CONCLUSION: The single 4-g APAP dose produced a transcriptome signature in PB cells characterized by down-regulation of oxidative phosphorylation genes accompanied by increased serum lactate. Similar gene expression changes were observed in rats and several patients after consuming hepatotoxic doses of APAP. The timing of the changes and the correlation with NAPQI production are consistent with mechanisms known to underlie APAP hepatoxicity. These studies support the further exploration of the blood transcriptome for biomarkers of DILI.
UNLABELLED: The diagnosis and management of drug-induced liver injury (DILI) is hindered by the limited utility of traditional clinical chemistries. It has recently been shown that hepatotoxicants can produce compound-specific changes in the peripheral blood (PB) transcriptome in rodents, suggesting that the blood transcriptome might provide new biomarkers of DILI. To investigate in humans, we used DNA microarrays as well as serum metabolomic methods to characterize changes in the transcriptome and metabolome in serial PB samples obtained from six healthy adults treated with a 4-g bolus dose of acetaminophen (APAP) and from three receiving placebo. Treatment did not cause liver injury as assessed by traditional liver chemistries. However, 48 hours after exposure, treated subjects showed marked down-regulation of genes involved in oxidative phosphorylation/mitochondrial function that was not observed in the placebos (P < 1.66E-19). The magnitude of down-regulation was positively correlated with the percent of APAP converted to the reactive metabolite N-acetyl-p-benzoquinone-imide (NAPQI) (r= 0.739;P= 0.058). In addition, unbiased analysis of the serum metabolome revealed an increase in serum lactate from 24 to 72 hours postdosing in the treated subjects alone (P< 0.005). Similar PB transcriptome changes were observed in humanoverdosepatients and rats receiving toxic doses. CONCLUSION: The single 4-g APAP dose produced a transcriptome signature in PB cells characterized by down-regulation of oxidative phosphorylation genes accompanied by increased serum lactate. Similar gene expression changes were observed in rats and several patients after consuming hepatotoxic doses of APAP. The timing of the changes and the correlation with NAPQI production are consistent with mechanisms known to underlie APAP hepatoxicity. These studies support the further exploration of the blood transcriptome for biomarkers of DILI.
Authors: George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee Journal: Ann Intern Med Date: 2002-12-17 Impact factor: 25.391
Authors: J L Loeffen; J A Smeitink; J M Trijbels; A J Janssen; R H Triepels; R C Sengers; L P van den Heuvel Journal: Hum Mutat Date: 2000 Impact factor: 4.878
Authors: J Y Chien; R M Peter; C M Nolan; C Wartell; J T Slattery; S D Nelson; R L Carithers; K E Thummel Journal: Clin Pharmacol Ther Date: 1997-01 Impact factor: 6.875
Authors: John Roiniotis; Hang Dinh; Paul Masendycz; Amanda Turner; Caryn L Elsegood; Glen M Scholz; John A Hamilton Journal: J Immunol Date: 2009-06-15 Impact factor: 5.422
Authors: Douglas A Keller; Daland R Juberg; Natasha Catlin; William H Farland; Frederick G Hess; Douglas C Wolf; Nancy G Doerrer Journal: Toxicol Sci Date: 2012-01-19 Impact factor: 4.849
Authors: Roman V Shchepin; Wei Liu; Huiyong Yin; Irene Zagol-Ikapitte; Taneem Amin; Byeong-Seon Jeong; L Jackson Roberts; John A Oates; Ned A Porter; Olivier Boutaud Journal: ACS Med Chem Lett Date: 2013-08-08 Impact factor: 4.345
Authors: Venkat R Pannala; Kalyan C Vinnakota; Shanea K Estes; Irina Trenary; Tracy P OˈBrien; Richard L Printz; Jason A Papin; Jaques Reifman; Tatsuya Oyama; Masakazu Shiota; Jamey D Young; Anders Wallqvist Journal: Toxicol Sci Date: 2020-02-01 Impact factor: 4.849